Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025
Caris Life Sciences (NASDAQ: CAI) announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025.
The company will host a conference call and live webcast on November 5 at 3:30 p.m. CT (4:30 p.m. ET) to discuss results. Investors can join the live webcast at https://edge.media-server.com/mmc/p/uwjxydsa. A replay will be available shortly after the call on the Investor Relations section of CarisLifeSciences.com.
Details
News Market Reaction – CAI
On Oct 23, the day this news came out, CAI closed 5.39% above the previous close.
Data tracked by StockTitan Argus for the Oct 23 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.
Conference Call Details:
Date: Wednesday, November 5, 2025
Time: 3:30 p.m. CT (4:30 p.m. ET)
Live Webcast: https://edge.media-server.com/mmc/p/uwjxydsa
A replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
Investor Relations:
InvestorRelations@CarisLS.com
917.689.3511
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-report-third-quarter-2025-financial-results-on-november-5-2025-302592156.html
SOURCE Caris Life Sciences
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.